Aclaris Therapeutics
ACRS
127 hedge funds and large institutions have $957M invested in Aclaris Therapeutics in 2022 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 48 increasing their positions, 26 reducing their positions, and 6 closing their positions.
217% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 6
85% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 26
12% more capital invested
Capital invested by funds: $851M → $957M (+$106M)
10% more funds holding
Funds holding: 115 → 127 (+12)
1% more call options, than puts
Call options by funds: $362K | Put options by funds: $357K
0.32% more ownership
Funds ownership: 95.03% → 95.35% (+0.32%)
0% more funds holding in top 10
Funds holding in top 10: 9 → 9 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$6.82M |
| 2 |
Walleye Capital
New York
|
+$4.25M |
| 3 |
Charles Schwab
San Francisco,
California
|
+$3.91M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$2.6M |
| 5 |
BlackRock
New York
|
+$2.21M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$22.8M |
| 2 |
Renaissance Technologies
New York
|
-$2.28M |
| 3 |
LCM
Laurion Capital Management
New York
|
-$2.13M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$1.55M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.53M |
ACRS Hedge Fund Activity: Q3 2022 in Review
127 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q3 2022, worth a combined $957M — up 12% from $851M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new ACRS positions and 6 closed out — a net gain of 13 holders — while 48 added to existing stakes and 26 trimmed.
The largest buyer was OrbiMed, adding an estimated $6.82M. The largest seller was Wellington Management Group, cutting an estimated $22.8M.
- 127 institutional investors held Aclaris Therapeutics (ACRS) as of Q3 2022, up from 115 in Q2 2022.
- Funds reported $957M of Aclaris Therapeutics stock for Q3 2022, up 12% quarter-over-quarter.
- 19 funds opened new Aclaris Therapeutics positions in Q3 2022 and 6 closed out, a net change of +13 holders.
- The largest Aclaris Therapeutics buyer in Q3 2022 was OrbiMed, an estimated $6.82M added.
- The largest Aclaris Therapeutics seller in Q3 2022 was Wellington Management Group, an estimated $22.8M sold.
Based on aggregated 13F filings for Q3 2022.